Neuroairmid Therapeutics Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

Neuroairmid Therapeutics General Information

Description

Developer of human neural stem cell technology designed for the treatment of neurodegenerative disorders. The company's technology utilizes pluripotent stem cell-derived neural stem cells to provide protective factors to the brain, thereby enabling healthcare providers to support neuronal function and address the progression of inherited neurodegenerative diseases.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • UCI Research Park, 5270 California Avenue
  • Suite 300
  • Irvine, CA 92617
  • United States
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • UCI Research Park, 5270 California Avenue
  • Suite 300
  • Irvine, CA 92617
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neuroairmid Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Neuroairmid Therapeutics‘s full profile, request access.

Request a free trial

Neuroairmid Therapeutics FAQs

  • Where is Neuroairmid Therapeutics headquartered?

    Neuroairmid Therapeutics is headquartered in Irvine, CA.

  • What industry is Neuroairmid Therapeutics in?

    Neuroairmid Therapeutics’s primary industry is Drug Delivery.

  • Is Neuroairmid Therapeutics a private or public company?

    Neuroairmid Therapeutics is a Private company.

  • What is the current valuation of Neuroairmid Therapeutics?

    The current valuation of Neuroairmid Therapeutics is .

  • What is Neuroairmid Therapeutics’s current revenue?

    The current revenue for Neuroairmid Therapeutics is .

  • When was Neuroairmid Therapeutics acquired?

    Neuroairmid Therapeutics was acquired on 13-Nov-2026.

  • Who acquired Neuroairmid Therapeutics?

    Neuroairmid Therapeutics was acquired by Lineage Cell Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process